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1. Introduction
Tumor and its embedding microenvironment form a unique, dynamic system, largely orch‐
estrated by cellular players, including fibroblasts and endothelial cells (EC), and surround‐
ing extracellular matrix (ECM) with its distinctive physical, biochemical, and biomechanical
properties. There is a general consensus that, beyond genetic mutations and epigenetic mod‐
ifications, the dialogue that occurs between tumor and its microenvironment, through solu‐
ble factors and molecular interactions, may affect tumor cells survival, growth, proliferation,
response to chemical/physical factors, and lies the basis for metastatization to distant, specif‐
ic organs. This theory was proposed by Paget in the 1880s [1], who underlined the need, for
investigating and targeting tumor, to focus not only on the cancer cell, “the seed”, but also
on the “soil” where tumor homes and in which it derives its nutrients, oxygen and signals
[2, 3]. Accordingly, tight links between tumor and surrounding microenvironment could de‐
termine the overall sensitivity to anti-cancer drugs and therefore represent an attractive
therapeutic target [4].
Tumor microenvironment plays a critical role also in development and progression of hae‐
matological malignancies [5,6]. In this regard, Multiple Myeloma (MM) represents a para‐
digmatic condition [5,6]. Indeed, MM plasma cells almost exclusively home and thrive
inside Bone Marrow (BM) microenvironment, which confers anti-apoptotic and pro-survival
signals and resistance to drugs. In turn, tumor cell interactions with BM cells and matrix re‐
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sult in re-shaping of microenvironment, and architectural changes involve in particular the
vascular compartment [7].
The establishment of tight links between MM plasma cells and their microenvironment un‐
derlines the need for appropriate models for studying MM biology and predicting the im‐
pact of drugs.
In  the  present  paper,  we  briefly  summarize  the  role  of  BM  microenvironment  and,
particularly,  of  MM  associated  angiogenesis,  in  MM  pathogenesis,  progression  and
prognosis.  We  then  provide  an  overview  of  the  currently  available  MM  models,  in‐
cluding  animal  models  and  a  new three-dimensional  (3D),  gel-based,  in  vitro  model  of
human MM microenvironment.  Finally,  we  discuss  the  potential  of  RCCSTM  bioreactor-
based,  dynamic  3D  model  systems  (cell  and  tissue  culture)  to  investigate  critical  as‐
pects  of  human  MM  pathobiology  and  possible  clinical  applications.  Advantages  and
limitations  of  each  model,  relative  to  MM  investigation  and  assessment  of  drug  sensi‐
tivity,  are  also considered.
2. Role of BM microenvironment and angiogenesis in MM progression
and prognosis
MM is a B-cell tumor, characterized by clonal proliferation of malignant plasma cells inside
the BM, production of a monoclonal paraprotein, and associated clinical features, including
lytic bone lesions, renal insufficiency, hypercalcemia and anemia. It accounts for approxi‐
mately 1% of neoplastic diseases and 13% of hematologic cancers. Albeit significant advan‐
ces have been recently achieved in the treatment of MM, the disease still remains incurable,
prompting the development of new therapeutic strategies [8].
MM  is  thought  to  evolve  from  a  pre-malignant  syndrome  known  as  Monoclonal
Gammopathy of  Uncertain  Significance  (MGUS),  that  progresses  to  smoldering (asymp‐
tomatic)  myeloma and,  finally,  to  symptomatic  myeloma.  In  addition  to  genetic  abnor‐
malities  accumulating  in  MM  cells,  BM  microenvironment  actively  participates  to  the
pathogenesis  and  progression  of  the  disease.  Indeed,  host  stromal  components  pro‐
foundly  influence  many  steps  of  tumor  progression,  such  as  tumor  proliferation,  inva‐
sion,  angiogenesis,  metastasis,  and  even  malignant  transformation  [9].  The  BM,  where
MM cells  specifically home,  provides a  highly specialized microenvironment,  which op‐
timally  “soils”  neoplastic  plasma cells,  and,  in  turn,  is  shaped by  the  interactions  with
MM cells  [5,6,10].
BM microenvironment consists of a series of cellular components, including hematopoietic
cells, immune cells, BM stromal cells (BMSC), osteoclasts, osteoblasts and endothelial cells
(EC), all embedded in an extracellular matrix (ECM) (Fig.1).
MM cells specifically localize inside the BM milieu through the CXCR4/CXCL12-SDF1-alpha
axis [11] and then interact with ECM and BM cellular components by means of adhesion
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molecules, including integrins. The complex interplay between MM cells and BM milieu, to‐
gether with the ensuing pathogenetic events, are depicted in Fig. 2 (upper panel).
1: erithrocytes; 2: megacaryocytes; 3: basophils; 4: adipocytes; 5: osteocytes; 6: B lymphocytes; 7: monocytes; 8: lining
osteoblasts; 9: osteoblasts; 10: osteoclasts; 11: hematopoietic stem cells “niche”; 12: T lymphocytes; 13: NK cells; 14:
eosinophils; 15: neutrophils; 16: monocytes; 17: stromal cells; 18: mesenchymal stem cells “niche”; 19: dendritic cells;
20: thrombocytes (platelets).
Figure 1. Bone Marrow microenvironment. Bone homeostasis is the result of a complex network of stimuli, includ‐
ing hormones, vitamins and physico-mechanical forces. In addition to osteoblats and osteoclasts, which are responsi‐
ble for bone deposition/resorption, BM microenvironment encompasses several cell types, like hematopoietic cells,
endothelial cells and mesenchimal cells, all embedded in a complex extra-cellular-matrix (ECM).
Interactions between MM cells and ECM and cellular components (Fig. 2, lower panel) trig‐
ger the release of soluble factors, which, in turn, determine autocrine/paracrine loops of MM
survival/proliferation and also promote osteoclastogenesis, defective immune functions and
the “angiogenic switch”, overall leading to MM cells growth, survival, and resistance to che‐
motherapeutic agents [10]. In particular, adhesion of MM cells to BMSC and to ECM compo‐
nents triggers anti-apoptotic signals and also the release of the pro-survival factor
Interleukin (IL)-6. Moreover, MM plasma cells and BM stroma release osteoclast-acivating
factors, including IL-1, IL-6, tumor necrosis factor (TNF)-α, RANK-L(Ligand) and Macro‐
phage Inflammatory Protein (MIP)-1α. MM cells have also a unique ability to evade im‐
mune surveillance through several mechanisms, including impairment of cytotoxic activity
and induction of dendritic cells dysfunction (Fig. 2).
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Figure 2. Interactions between MM cellsand BM microenviroment. Upper panel: schematic representation of MM
cells inside BM microenvironment; the soluble factors involved in the major pathogenetic events, including tumor pro‐
liferation/survival, angiogenesis, osteoclastogenesis and defective immune function are depicted. Lower panel illus‐
trates the major growth factor receptors and adhesion molecules used by MM plasma cells to interact with ECM and
cellular components of BM microenvironment
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Angiogenesis, the sprouting of capillaries from existing blood-vessels, is a complex, dynam‐
ic and tightly regulated process, that occurs physiologically during normal growth, wound
repair after injury and regeneration [12,13]. Angiogenesis is controlled by the balance be‐
tween positive and negative regulators. In a tumor microenvironment, the exaggerate ex‐
pression of pro-angiogenic cyto-chemokines starts the ‘‘angiogenic switch’’, leading to
increased micro vessel density (MVD) [14]. The occurrence of an “angiogenic switch”, re‐
sponsible for the transition from the avascular “dormant” phase to the vascular phase of ex‐
ponential tumor growth [15,16], has also been proposed for MM. Pro- and anti-angiogenic
soluble molecules are produced and released by myeloma cells and components of microen‐
vironment, including MMEC, stromal cells and inflammatory cells [17-19] (Fig.2 A, upper
panel). Major angiogenic cytokines are VEGF-A, fibroblast growth factor (FGF) and hepato‐
cyte growth factor (HGF). Both EC in general, and in particular MMEC, and MM cells se‐
crete VEGF and express its receptors, thereby contributing to autocrine/paracrine pathways
of tumor growth, survival and angiogenesis [19]. Finally, Angiopoietins (Angs, Ang-1
and-2) are important mediators in vasculature homeostasis and their circulating levels are
considered of prognostic significance in MM [20].
Overall, BM angiogenesis in MM contributes to disease progression; accordingly, new anti-
myeloma agents target not only MM cells, but also the microenvironment, and in particular
vessels [21]. This notion is exemplified by the proteasome inhibitor Bortezomib (PS-341, Vel‐
cade), which has been approved for treatment of patients with relapsed and refractory MM and
more recently used in front-line therapy for the disease. In vitro, proteasome inhibition by bor‐
tezomib causes apoptosis in both solid tumor and haematological malignancies, particularly
MM [22]. More recently, Bortezomib has also been reported to affect viability of angiogenic EC,
as shown in in vitro experimental conditions as well in animal models [23,24]. Notably, neither
reliable biomarkers measurable in vivo nor ex vivo models of human BM microenvironment are
currently available to assess the anti-angiogenic effect of drugs in MM patients.
3. Advantages of models which mimic tumor microenvironment
exploiting the third dimension
Since BM microenvironment is of most importance in supporting myeloma cell growth and
survival, experimental models of MM should provide insights into the mechanisms that, at
molecular level, regulate the complex interplay between MM cells and biochemical and
physical cues coming from BM ECM and cell components.
Traditional two-dimensional (2D) in vitro models (static culture of single cells kept as mono‐
layer on flat, artificial surfaces) still represent the most popular models for in vitro studies,
even if they present severe limitations, being unable to reproduce the behaviour and physio‐
logical responses of various normal and pathological cell types/tissues. It is now generally
accepted that any attempt aimed at the generation of reliable and physiologically relevant in
vitro tissue analogues, tumors included, should take into account the need of reproducing
(or preserving) the specific characteristics of their original microenvironment, which in‐
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clude, in addition to tissue-specific multiple cellularity, biochemical and mechanical proper‐
ties, also the three-dimensionality [25,26]. Since the pioneering studies of Bissell and
colleagues [27], different groups, including ours, have demonstrated that significant differ‐
ences exist between the biological behaviour and gene expression profiles of normal and
transformed/tumor-derived cells maintained in culture with traditional (2D) culture meth‐
ods, and that of cells kept in 3D culture (see, for example, 28-31), proving that 3D models
can mimic in vivo conditions better than 2D systems [26,32,33].
Table 1 illustrates the principal characteristics of 3D versus conventional 2D in vitro models
of differentiated and tumoral tissues, and their relevance to the in vivo situation.
Characteristics of
the
in vitro models
2D conformation
(on flat glass or plastic
substrates)
3D conformation
(cell spheroids, 3D artificial
supports)
References
In vitro models of differentiated tissues
Architecture MonolayerLack of 3D physical cues
Multilayer
Nano- and micro-topographies
are recreated
34-37
Cell-milieu
interaction
Unidirectional, passive fluid
diffusion
Lack of chemical gradients and
reduced gas supply
high ECM stiffness (more than 1
GPa)
Pluri-directional active fluid
diffusion
Gradients of nutrient and gas can
be generated
Efficient waste removal in
dynamic bioreactors
ECM stiffness lower than in 2D
(variable from 1 to 100 kPa)
26, 38-41
Cell-cell
interactions
Reduced interactions between
neighbouring cells
Increased interactions between
neighbouring cells 25
Cell morphology/
viability
Flat: geometrically-constrained
baso-apical polarity
Limited spatial distribution of
adhesions to ECM
Limited cell survival rate
Spheroid: free cell polarity guided
by ECM
Whole cell surface distribution of
adhesions to ECM
High cell survival rate
3142-44
Ability to mimic the
physiological
behaviour of cells
in vivo
Lack the major physiological
cues (biochemical, chemical,
physical, mechanical) of the
original tissue
Low cell differentiation state
and function
3D models are closer to the in vivo
condition and number of in vivo
cell/tissue features can be
reproduced
High differentiation state and
functional competence
ECM characteristics may vary,
according to the culture model,
41, 45,46, 47
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Characteristics of
the
in vitro models
2D conformation
(on flat glass or plastic
substrates)
3D conformation
(cell spheroids, 3D artificial
supports)
References
Absent or abnormal neo-
synthesized ECM (qualitatively
and quantitatively)
from synthetic, natural and de-
cellularized ECM, but 3D models
are closer to the physiological
context
In vitro models of tumor tissues
ECM-related cell
motility and
mechanobiology,
compared to the in
vivo situation
- ++ 48 49
Cell organization Organized Disruption of tissue organization,as in in vivo tumours 50
Gene expression
Higher growth-/ metabolic-
related gene expression
Activation of mitochondrial and
ribosomal gene clusters
Gene expression is, generally,
quite different from in vivo
tumours
Growth-arrest related genes are
activated
Closer to tumour tissue in vivo
51-53
Capability to
reproduce specific
morphological and
behavioural
characteristics of in
vivo malignant
cells
+/- ++ 54,55
Responsiveness to
surviving signal
from ECM
+ ++ 55
Drug resistance
(sensitivity) Low (high) High (low) 56-58
Capability to
reproduce the
complexity of
tumour
microenvironment
- +/ +++ 56 59,60
Table 1.
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In an effort to reproduce in vitro the 3D specific microenvironment of the parental tissue, taking
advantage of the rapid development of new technologies and tissue engineering techniques,
an extremely wide variety of tissue models have been produced. The latter have already been
successfully applied for investigating critical aspects of in vivo behaviour of a number of nor‐
mal and tumoral cells (reviewed and discussed in 26). On this basis, 3D culture systems have
been proposed as the most physiologically relevant in vitro models to investigate tumor devel‐
opment and behaviour [60-62]. Recently, this experimental approach has been also exploited
for the study of MM-cell biology and sensitivity to therapeutic agents [63].
Within this context, 3D in vitro (cell-based)/ex-vivo (tissue-based) human-derived culture
systems represent important tools to generate new approaches to the understanding of the
molecular mechanisms of MM progression, essential prerequisites for the development of
more effective interventional, diagnostic and prognostic strategies.
4. Murine models of MM
4.1. Subcutaneous xenograft models
The simplest way to generate an animal model of cancer consists in the injection of tumor
cells into an immune-deficient mouse. This approach, known as the xenograft model, has
been extensively employed for solid tumors [64,65] and then extended to MM. The xeno‐
graft model of MM consists in the subcutaneous injection of 1-2 x 107 human myeloma cells
(from RPMI-8226, U266, ARH-77 or OPM-2 cell lines) into the flanks of Severe Combined
Immune-Deficient (SCID), nonobese diabetic (NOD), SCID/NOD and SCID/beige, mice
[66,67] (Fig.3A). The resulting plasmacytoma is palpable, and tumor burden measurable
with a pair of caliper or, when lines are transduced with the eGFP-luc fusion gene, by biolu‐
minescence imaging [68]. After harvesting, tumor mass is suitable for histological examina‐
tion, allowing identification of vasculature and determination of cell proliferation/apoptosis.
The model is currently used to assess the activity of new drugs on MM tumor growth and to
establish the effective, minimally toxic, dose. As an example, this model has been employed
to investigate the in vivo anti-myeloma effect induced by the mTOR inhibitor CCI-779 [69].
More recently, the efficacy of new inhibitors of the CXCR4/CXCL12 axis (AMD3100 and
BKT140) [70], and of stressors of the endoplasmic reticulum (spicamycin analogue,
KRN5500) [71], which inflict death of MM cells, have been demonstrated using the xenograft
model. Besides mono-therapies, the model is suitable to evaluate the maximal effect, in
terms of tumor volume reduction, obtainable with combined molecules [72].
While the xenograft model is extremely practical, particularly for drug testing, it still suffers
from several limitations. In fact, it does not accurately mimic human disease, since myeloma
cell lines do not behave as primary myeloma cells, more closely resembling the aggressive
stage of plasma cell leukemia. More importantly, it fails to recapitulate the reciprocal interac‐
tions between MM cells and their microenvironment, which follow MM cell localization and
retention inside the BM. As a result, drug efficacy can be over-estimated, lacking implanted
MM cells the specific, proper human context of ECM and non-malignant accessory cells.
Multiple Myeloma - A Quick Reflection on the Fast Progress46
Murine  models  of  MM,  including  the  5TMM model,  contribute  to  overcome  this  latter
limitation.
Figure 3. Schematic representation of currently available MM animal models. The major murine (m) and murine-
human(hu) models together with their main advantages and limitations are depicted. Synth = synthetic polymeric
scaffold; BMSC= Bone Marrow Stromal Cells; SCID=severe combined immune deficient.
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4.2. 5TMM models
The 5T model has been developed in the late seventies upon injection of mice with syngene‐
ic murine MM cells, spontaneously arising in elderly C57BL/KaLwRij mice [73,74]. The
group of MM murine models collectively indicated as 5TMM mice comprises different types
of mice, each bearing different tumor cells and having distinct characteristics (Figure 3B).
The most commonly used, the 5T2MM and the 5T33MM models, display selective localiza‐
tion of cells in the BM, the presence of a serum M component and increased BM angiogene‐
sis. The first one is characterized by moderate growth and development of osteolytic lesions
more closely reproducing the human disease, while the second one displays a more aggres‐
sive behaviour with rapid growth [75].
Studies based on these models, substantially contributed by Karin Vanderkerken’s group,
have provided valuable insights into MM biology, and in particular on the mechanisms re‐
sponsible for bone disease, MM-associated neoangiogenesis, and MM cell homing to the BM
[75]. Indeed, taking advantage from these models, it has been possible to dissect the single
steps which participate to the homing process, including chemo-attraction, adhesion, trans-
endothelial migration and invasion, and also to identify the molecular pairs involved [75].
Moreover, these models allow the assessment of the impact of drugs on MM cells inside
their proper microenvironment. In particular, the 5T2MM model allowed to unravel the an‐
ti-tumor activity, in addition to prevention of bone resorption, of the amino-biphosphonate
zolendronic acid [76]. More recently, the novel ‘second-generation’ pyrimidyl-hydroxamic
acid-based histone deacetylase inhibitor JNJ-26481585 was found to reduce tumor burden
and also to affect angiogenesis and osteolysis [77].
A major limitation of the model is represented by the limited availability of different 5T cell
lines, which fails to recapitulate the high variability both in terms of genetics and of tumor
behaviour which characterize MM developing in humans. Moreover, the results obtained
with 5T models should be interpreted with caution, given the potential differences in the bi‐
ology of human vs murine myeloma.
4.3. SCID-hu and SCID-synth-hu models
In an attempt to “humanize” murine models, in 1997 Urashima established an in vivo model
of human MM using SCID mice bilaterally implanted with human fetal bone grafts (SCID-
hu mice) [78]. The purpose was to study the role of adhesion molecules which participate to
human MM-BMSC interactions and regulate MM cell homing. The original experimental de‐
sign consisted in the injection of MM cell lines (ARH-77, OCI-My5, U-266 or RPMI-8226)
(1x104-105) into the BM cavity of the left bone implants in irradiated mice (Fig.3C). Human
monoclonal MM cells grew within the human BM replacing the stroma and metastatized to
the controlateral right bone implant, but not to murine bones or other murine organs [79],
suggesting the existence of species-specific interactions. In myeloma-bearing mice, circulat‐
ing human Ig were detectable and mice developed tubular nephropathy, due to light chains
deposition, closely mirroring MM clinical manifestations and physiopathology [79]. The
model was successfully employed to study the efficacy of thalidomide as an anti-myeloma
drug, disclosing its anti-angiogenic properties [80]. The engraftment of IL-6-dependent
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INA-6 cells in SCID-hu mice, but not in SCID mice, as well as their sensitivity to anti-myelo‐
ma agents, has also been documented [81].
More recently, Pierfrancesco Tassone and Filippo Causa developed the so-called “SCID-
synth-hu” model (Figure 3D), based on the implantation of artificial bone scaffolds repopu‐
lated with human BMSC into SCID mice, followed by injection of purified MM cells from
patients [82] (Fig. 3D). This model represents a further advancement over the previously de‐
scribed SCID-hu mouse (Fig. 3C). In fact, the use of 3D poly-β-caprolactone polymeric scaf‐
folds, closely reproducing the micro-architecture of a human bone, overcomes the restricted
availability of human fetal bones for implant, and also allows to perform studies in the con‐
text of an autologous setting [82].
As for SCID-hu models, in SCID-synth-hu mice injected human MM cells were found to op‐
timally engraft the implanted “niche” and to interact with the human bone milieu, as dem‐
onstrated not only by histological and immunohistochemical analyses of the retrieved
implants, but also by demonstration of immungloglobulin production in vivo [82].
Both systems thereby offer the possibility to investigate human MM cells-BM microenviron‐
ment interactions and to perform pre-clinical testing of anti-MM drugs in a clinically rele‐
vant context.
4.4. Transgenic models
MM cells accumulate a series of somatic mutations in the initiating and progressing phases
of the disease [10], thus justifying development of genetically modified MM murine models,
which recapitulate and explore the genetics of MM [83]. Recently, a model has been devel‐
oped based on the enforced B cell lineage-directed transgene expression of XBP-1s [84].
XBP-1 is a major regulator of the Unfolded Protein Response (UPR) and plasma cell differen‐
tiation. Moreover, XBP-1 over-expression has been implicated in human carcinogenesis and
tumor growth in solid tumors and also in MM [84]. XBP-1 transgenic mice spontaneously
develop MGUS which progresses to MM, exhibiting remarkable clinical features common to
human MM. In particular, BM involvement with clonal MM cells, serum M spike, bone lytic
lesions and renal Ig deposition could be demonstrated [84].
Another model exploited the deregulated expression of Myc. Myc activation occurs in post-
germinal center malignancies, including Burkitt’s lymphoma, and is a common feature in
MM; in particular its over-expression is generally considered of prognostic significance [85].
Mice engineered to express c-Myc under the control of mouse immunoglobulin kappa (IgK)
light-chain gene–regulatory elements (Vk-Myc mice) were developed [86]. Myc is a strong
oncogene, and its constitutive expression in early B cells of Vk-Myc mice led to a very ag‐
gressive lymphoma, with extra-medullary localization [86].
To create a transgenic mouse model more closely resembling human MM, in their elegant
work Chesi and co-workers selected the C57Bl6 strain, genetically predisposed to develop
MGUS, and generated a vector (Vk*Myc) containing a stop codon insertion in the human c-
myc oncogene, which prevented its expression [87] (Fig. 3E). Myc could be then sporadically
activated in post-germinal B cells as a result of somatic hypermutation, leading to the transi‐
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tion from the spontaneous monoclonal gammopathy to a disease that fully recapitulate the
biological and clinical features of human MM. In fact, Vk*Myc mice are characterized by the
accumulation of slowly proliferating plasma cells exclusively inside the BM. Moreover, high
levels of monoclonal antibody are detectable and end-organ damage develops, including
anemia, kidney failure and lytic bone disease [87]. The model was found to be highly predic‐
tive of the activity of anti-myeloma drugs [88], including those that target microenviron‐
ment, and may potentially help to select new agents for evaluation in clinical trials.
5. Human-derived models of MM
5.1. 3D in vitro /ex-vivo human-derived models of MM
Due to inter-species differences, animal models have incomplete predictive value for human
MM disease and drug response. New models are, therefore, needed that more closely re‐
semble the in vivo situation in patients. Reliable, human-derived in vitro models, able to re‐
produce myelomagenesis within the specificity of BM microenvironment, are therefore of
extreme value.
Kirshner and her group have reconstructed, in vitro, human BM microenvironment, through
the proper overlay of matrix components, on which isolated cells from BM aspirate of MM
patients were seeded [63]. Cells spontaneously redistributed throughout the gel-matrix 3D
substrate, mimicking human BM architecture and BM-MM interactions, thus providing a
powerful tool for understanding the biology of MM [89]. Strikingly, reconstructed BM al‐
lowed the expansion of primary myeloma cells, including the putative stem cell fraction.
Moreover, the model allowed the assessment of the impact of anti-MM drugs on distinct cel‐
lular compartments inside a 3D architecture [63].
5.2. 3D culture of human MM isolated cells and tissue explants in the microgravity-based
RCCSTM bioreactor
It is well known that the metabolic requirements of complex 3D cell constructs are substan‐
tially higher than those needed for the maintenance of traditional cell monolayers (2D cul‐
ture) kept in liquid media under static conditions. Dynamic bioreactors were primarily
developed to modulate mass transfer, a crucial element for guaranteeing gas/nutrient sup‐
ply and waste elimination, essential factors for maintaining cell viability within large 3D
cell/tissue masses. Despite a wide array of fluid-dynamic bioreactors has been devised
[47,90], the low-shear environment and optimal mass transfer, needed for the long-term cul‐
ture of functional 3D tissue constructs and explants, were attained only with the introduc‐
tion of the microgravity-based Rotary Cell Culture System (RCCS™, Synthecon Inc., USA)
bioreactors (91,92; a vast literature is also available at http://www.synthecon.com). The rele‐
vance of this technology in enabling the long-term culture of complex tissue-like engineered
3D bio-constructs and tissue explants of various origin has been demonstrated also by our
group, and, namely, in the case of bone [31,47.93].
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On this basis, we successfully employed the microgravity-based RCCSTM technology for the
generation (and long-term maintenance) of viable human-derived MM tissue explants and
3D cell constructs. Fig. 4 shows the culture chamber of the RCCS™ microgravity-based bio‐
reactor, and histo-morphological images of the ex-vivo models of human MM developed by
our group. Isolated cells from the RPMI myeloma cell line, kept in Bioreactor, spontaneously
self–aggregated forming spheroid-like structures which retained viability and were identifi‐
able with the specific anti-CD38 monoclonal antibody (Fig.4B).
Figure 4. RCCS TM-based 3D ex-vivo models of MM developed by our group. A: Detail of the culture chamber of
the RCCS™ microgravity-based bioreactor; B: Monotypic 3D multi-cellular spheroids (RPMI cell line) cultured for 1
week in the RCCS™ bioreactor (H&E staining, left panels; CD38 staining, right panels); C: 3D tissue culture of skin biop‐
sies (1 week) showing intact architecture and identifiable blood and lymphatic (D2-40+) vessels D: MM tissue explants
cultured for 3 days in the RCCS™ bioreactor (H&E staining), in the absence or presence of Bortezomib, the latter show‐
ing plasma cells death. Arrows indicate bone lamellae.
The suitability of our method for the culture of human tissue samples was, firstly, proved by
using skin biopsies, which retained intact epidermal and dermal architecture, including ker‐
atin stratum and skin annexes. Moreover, both blood and lymphatic vasculature was identi‐
fiable and exhibited normal morphology, in particular patent lumen and complete
endothelial lining (Fig.4C). The 3D culture of thick sections of human MM tissue explants
fully preserved tissue architecture and microenvironment integrity (Fig.4D) for extended pe‐
riods of time. Moreover, the system was suitable for the assessment of drug sensitivity, not
only of tumor compartment, but also of angiogenic vessels (Fig.4D). Indeed, quantification
of MVD in treated specimens could represent a unique method to assess the anti-angiogenic
effect of a drug in human samples ex vivo. Finally, specialized functions of both MM cells
and their microenvironment, including beta-2 microglobulin and cytokine release and met‐
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alloproteases activities, could be also assessed (M. Ferrarini et al., submitted). Overall, these
observations suggest that the 3D culture model in Bioreactor can be exploited as a novel
translational tool, allowing prospective pre-clinical toxicity and drug efficacy testing in indi‐
vidual patients.
6. Conclusions
A major challenge in cancer biology and cancer therapy relies in the availability of suitable
models that recapitulate the complex tumor-host interplay and responsiveness to drugs. This
is especially true for MM, where the existence of tight links between MM cells and BM micro‐
environment has hampered for long the development of adequate animals and in vitro mod‐
els. Recently, innovative murine and chimeric in vivo models have been developed, which
allowed both to investigate MM physiopathology and to perform drugs testing. On the other
hand, the exploitation of novel technologies for ex-vivo 3D culturing of human MM samples is
emerging as a tool to properly investigate its pathogenetic mechanisms (and interactions)
within a human context, and also to predict response to drugs in individual patients.
The availability of more and more sophisticated systems is expected to pave the way to a
deeper understanding of pathogenetic events and also to development of novel patients-tail‐
ored therapeutic strategies.
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